Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey

Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey

Objectives To evaluate outcomes and cost-effectiveness of targeted therapy sequencing for metastatic and recurrent cervical cancer. Method Models were simulated based on phase II and III trials on bevacizumab (bev) from GOG-240, cemiplimab (cemi) from GOG 3016, pembrolizumab (pembro) from KEYNOTE-82...

Full description

Bibliographic Details
Main Authors: Michael T. Richardson MD, Kristopher Attwood PhD, Gabriella Smith MD, Su-Ying Liang PhD, Katherine LaVigne Mager MD, Krishnansu S. Tewari MD, Robert L. Coleman MD, Daniel S. Kapp PhD, MD, John K. Chan MD, Bradley J. Monk MD
Format: Article
Language:English
Published: SAGE Publishing 2023-06-01
Series:Cancer Control
Online Access:https://doi.org/10.1177/10732748231182795

Internet

https://doi.org/10.1177/10732748231182795

Similar Items